TGR-1202 shows promise in CLL and DLBCL
TGR-1202 is a novel PI3K inhibitor currently being tested in the clinical setting for chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL). In the following videos and presentation, the trial chairs provide insight into its novel mechanism of action and potential in the clinical setting.
The content is sponsored by TG Therapeutics.
Our current understanding of TGR-1202, including a detailed overview of the seemingly unique mode-of-action, and how this stands out among the PI3K class of products.
The latest news from the UNITY-DLBCL clinical trial, looking at TGR-1202 in the treatment of diffuse large B-cell lymphoma. Including an overview of how this will help us learn more about the class of PI3K inhibitors, and the potential benefits that patients could see from this in the future.
Prof. John Gribben discussed the great advances we are making with novel combinations, and how these are demonstrating favourability over current standard of care.
The webcast is presented by Dr Owen O'Connor and Prof. John Gribben, discussing the development of the UNITY clinical trials and describing the latest exciting data in detail.